Recognizing Inadequate Response to First-Line Therapy in PBCUDCA at 13 to 15 mg/kg/day is the established first-line therapy for PBC, and patients who achieve a good biochemical response on it have a...3 min read
The Invisible Burden of Fatigue and Brain Fog in PBCFor the clinician, a well-controlled case of primary biliary cholangitis (PBC) is often defined by the numbers: a falling alkaline phosphatase (ALP), a normal bilirubin, and a reassuring disease stage. Yet...3 min read
Why PBC Patients Underreport the ItchPruritus affects roughly two-thirds of patients with PBC over the disease course, and evidence consistently shows that its severity is decoupled from the laboratory picture. The result is...3 min read
Extrahepatic and Long-Term Comorbidity Management in PBCPBC is a systemic autoimmune disease, not a purely hepatic one, and its management extends well beyond the liver. Patients carry an elevated burden of extrahepatic autoimmune conditions...3 min read
Test Your PBC Clinical Decision KnowledgePrimary biliary cholangitis (PBC) management encompasses serologic and biochemical diagnosis, risk-stratified treatment decisions, and long-term surveillance. The following 5 questions span that...1 min read
Second-Line Treatment Options After Inadequate UDCA Response in PBCWhen a patient with primary biliary cholangitis (PBC) has an inadequate response to – or cannot tolerate – first-line UDCA, the question is no longer...3 min read
Managing Cholestatic Pruritus in PBCPruritus is one of the most burdensome symptoms of primary biliary cholangitis (PBC), affecting roughly 2 of 3 patients over the disease course...3 min read
Hear+Now – An AI-Powered Audio Digest: When PBC Patients Outpace the Treatment ConversationModern clinicians often underestimate a patient's readiness for advanced clinical dialogue. Data reveals that individuals living with primary biliary cholangitis are independently...3 min read
